For some time, there has been evidence to suggest a drug used to treat type 2 diabetes could slow certain types of cancers. Until now, we didn’t know why.
The First 1,000 Days Program aims to prevent the development of obesity among mother-infant pairs.
Mass General is a leader in the field of digital pathology, which increases the accuracy of diagnoses from biopsies and expands what they can tell us about patient health.
In 1994, Aldiana Soljic fled Bosnia as a refugee. Now, she is a world-class urologist, and in 2014 she became the first general urologist at Mass General.
Priscilla Brastianos, MD, is leading a research effort to understand the molecular and genomic drivers of metastatic brain tumors and develop more effective treatments.
Inspiring thousands to join them, Dick and Marcy DeWolfe partnered with Ann and Desmond Heathwood to lead the MGH Fund to reach and surpass its highest fundraising goal to date.
Advised to seek out the leading authority on his form of lung cancer, Yariv “Dolio” Kafri found a Mass General Cancer Center doctor with a promising new drug.
Work by a Mass General team of physician-researchers has led to a more effective treatment against a common form of lung cancer.
A lifelong healthcare journey at MGH involving kidney stones, gall bladder surgery and even the birth of two grandchildren convinced computer expert Howard Sternlieb that he was a lucky man.
The Mass General Diabetes Unit is working toward a cure for the disease while making new and effective strides in prevention and treatment.